Treatment of Liver Transplant Recipients Who Have Chronic Hepatitis C Virus Infection
|
|
- Charlene Wilkerson
- 5 years ago
- Views:
Transcription
1 Lecture Treatment of Liver Transplant Recipients Who Have Chronic Hepatitis C Virus Infection Murat Korkmaz Abstract Chronic hepatitis C virus infection is the most common cause of chronic liver disease and indication for liver transplant in Western countries. Viral infection may recur after transplant in most patients. The diagnosis of histologic recurrence of hepatitis C virus infection after liver transplant may be difficult and may be confused with acute cellular graft rejection. Characteristics of the recipient, donor, virus, and transplant may be associated with disease progression. Treatment of hepatitis C virus infection has a positive effect on the outcome of liver transplant. There are 3 approaches used to minimize recurrent hepatitis C virus infection after liver transplant: antiviral therapy before transplant, antiviral preventive and preemptive treatment after transplant, and treatment of established reinfection. Protease inhibitors are being evaluated in patients who have severe hepatitis C virus recurrence after liver transplant. Liver graft survival is less frequent after revision transplant. Several new drugs currently are being evaluated in clinical trials for treatment of hepatitis C virus infection. Key words: Antiviral therapy, Cirrhosis, Diagnosis, Interferon, Ribavirin, HCV Introduction Chronic hepatitis C virus (HCV) infection is the most common cause of chronic liver disease and indication From the Department of Gastroenterology and Hepatology, Baskent University, Faculty of Medicine, Ankara, Turkey Acknowledgements: The authors have no conflicts of interest, and there was no funding for this study. Corresponding author: Murat Korkmaz, Fevzi Cakmak Cad. 10. Sokak. Gastroenteroloji Polk., Bahçelievler, Ankara, Turkey Phone: Fax: murat71korkmaz@yahoo.com Experimental and Clinical Transplantation (2014) Suppl 1: for liver transplant in Western countries. 1 In Turkey, 15% liver transplants are performed for HCV infection. With increased prevalence of chronic liver disease, demand for liver transplant, and HCV-related death, health issues associated with HCV may become more prevalent in the future. Viral infection may recur after transplant in most patients, and the rate of progression of fibrosis is faster with higher stages of fibrosis and reduced time in a given stage of fibrosis. 2 Histopathologic changes associated with acute HCV infection appear at 4 to 12 weeks after transplant. Most patients experience HCV-related problems, and histologic features of chronic HCV infection may be demonstrated in 70% to 90% recipients at 1 year and 90% to 95% at 5 years after transplant. Cirrhosis may recur at median 8 to 10 years after transplant, and 30% patients develop cirrhosis within 5 years. After cirrhosis develops, annual decompensation occurs in 30% to 40% patients. 3 Although 50% patients have mild to moderate inflammation on liver histology, 10% patients develop severe recurrence with cholestatic features. Patients who are not treated usually die within 6 months after transplant. 4 In patients who had liver transplants, HCV infection had a major effect on patient and graft survival. 5 The frequency of survival of the graft and patient at 5 years is 20% to 25% lower in liver transplant recipients who do not have HCV infection. Diagnosis The diagnosis of histologic recurrence of HCV infection after liver transplant may be difficult and may be confused with acute cellular graft rejection. The level of HCV RNA and liver biopsy are important to confirm the diagnosis, stage the disease, Copyright Başkent University 2014 Printed in Turkey. All Rights Reserved. DOI: /ect.25Liver.L23
2 Murat Korkmaz /Experimental and Clinical Transplantation (2014) Suppl 1: and plan treatment. Protocol biopsies are recommended annually or when clinically indicated. Factors Associated With Hepatitis C Virus Disease Progression Characteristics of the recipient, donor, virus, and transplant may be associated with disease progression. Factors associated with the recipient that negatively affect progression of HCV disease are older age, African American race, and coinfection with human immunodeficiency virus. The recipient and donor IL28B non-cc genotype may be a strong positive predictor of recurrence and response to therapy. 6 After liver transplant, cytomegalovirus and human herpesvirus 6 infections are associated with rapid progression of HCV recurrence. 7 Cytomegalovirus infection and disease are associated with more severe fibrosis in patients who have HCV infection. Donor-related factors that may predict disease progression and risk of graft loss include older donor age, especially donor age > 40 years. 8 The outcomes of liver transplant performed with donors that have anti-hcv antibodies are similar to liver transplant with HCV-negative organs. 9 Previous studies reported different outcomes with living or deceased donors, but results of living- and deceased-donor liver transplant are similar at centers experienced with living-donor liver transplant. 10 After performing 20 living-donor liver transplants, the transplant center has achieved adequate experience. The effect of donor steatosis on the outcome of graft survival is controversial. Mild steatosis may be safe, but donor steatosis > 30% may be a risk factor for early and severe recurrence of HCV infection. 11,12 There is controversy about the effect of mismatch between donor and recipient human leukocyte antigen (HLA) profile on HCV recurrence and severity of disease after liver transplant. In addition, the severity of HCV recurrence may be affected by gene polymorphisms in the allograft for cytokines such as tumor necrosis factor β, interleukin 16, transforming growth factor β, interleukin 10, and interferon γ. 13 Viral factors that may be predictors of recurrence include high viral load in the recipient before transplant and status of genotype 1b. In a European multicenter study with 15 centers and 652 patients, genotype 1b was an independent risk factor for recurrent hepatitis but not patient or graft survival. 14 However, other studies showed no difference in the frequency or severity of hepatitis, graft survival, or patient survival between patients who had or did not have genotype 1b. 16, 17 Several reports suggested that viral load before or after transplant did not correlate with the severity of liver disease or predict the timing of HCV recurrence after transplant, but another study showed an association between increased viral titers and worse histologic activity, increased risk of fibrosis, and decreased survival Transplant-related factors that may be associated with progression of HCV disease include immunosuppressive treatment. Steroid maintenance therapy has no detrimental effect on graft or patient survival. However, some treatments against rejection are associated with HCV disease severity and progression, such as corticosteroid boluses, rapid corticosteroid tapering, and antilymphocyte preparations. Therefore, mild rejection is treated with increased maintenance immunosuppression and not corticosteroid boluses. 20 In 2 randomized, prospective, multicenter trials with liver transplant patients who had chronic HCV infection, the steroid-free regimen was safe and effective, but there was no advantage between immunosuppressive regimens with respect to HCV recurrence. 21,22 The use of steroids in HCV-infected recipients is not contraindicated. No single drug or combination immunosuppressive regimen that may minimize histologic progression of HCV disease. Cyclosporine may inhibit HCV replication in vitro, but tacrolimus does not inhibit HCV replication in vitro. A meta-analysis that compared immunosuppression with tacrolimus or cyclosporine in HCV-infected recipients included 5 randomized, controlled trials and 366 patients, and there were no significant differences between regimens in mortality, graft survival, biopsy-proven acute rejection, steroid-resistant rejection, or fibrosing cholestatic hepatitis. 23 Nevertheless, some authors suggest that immunosuppression with tacrolimus may be better than cyclosporine or sirolimus, but there is controversy about the effect of sirolimus in minimizing fibrosis progression in patients who have HCV infection. 24 Treatment Treatment of HCV infection has a positive effect on the outcome of liver transplant. After patients
3 30 Murat Korkmaz /Experimental and Clinical Transplantation (2014) Suppl 1: Exp Clin Transplant achieve sustained viral response, 97% to 100% patients have negative tests for HCV RNA at longterm follow-up. When recipient HCV RNA levels are negative during transplant, the frequency of HCV recurrence is lower. The best strategy to prevent the recurrence of HCV is to eradicate HCV infection before liver transplant. There are 3 approaches used to minimize recurrent HCV infection after liver transplant: antiviral therapy before transplant, antiviral preventive and preemptive treatment after transplant, and treatment of established reinfection. Antiviral therapy before transplant Treatment to suppress HCV viremia before transplant in patients on the transplant waiting list may reduce the risk of graft reinfection. The aim of antiviral therapy before transplant is to achieve negative serum HCV RNA levels during transplant. Suppression of HCV RNA in patients who have advanced disease is achievable in 10% to 50% patients, and 20% to 30% treated patients may remain without HCV infection after transplant. 25,26 Factors that predict virologic response in patients who have advanced stages of chronic HCV infection have been recognized. Factors predictive of sustained viral response in 124 patients with advanced HCV infection include (1) infection with HCV genotype 2 or 3 (in contrast with genotypes 1, 4, or 6), (2) Child- Pugh class A cirrhosis (in contrast with Child-Pugh class B or C), and (3) dose and duration of interferon or pegylated interferon and ribavirin treatment. 27 A randomized, controlled trial evaluated treatment of chronic HCV using pegylated interferon plus ribavirin before transplant to prevent recurrent HCV infection after transplant. 28 In 30 patients who had genotype 1, 4, or 6 and who were treated for HCV infection, 23 patients had liver transplant, and 22% who had transplant achieved a virologic response after transplant. Major adverse events were similar in the treated and untreated groups, and patients who had 16 weeks treatment before transplant achieved the highest frequency of virologic response after transplant. 28 However, treatment was associated with an increased frequency of major adverse events including infections. In this trial, virologic response after transplant was only possible in patients who had negative levels of HCV RNA by week 12. Predictors of viral clearance included genotypes other than genotype 1 and an early virological response. Patients who previously did not respond to interferon and ribavirin are not suitable for HCV treatment before transplant because the likelihood of achieving undetectable HCV RNA level is very low (< 10%). Patients who had previous relapse may be suitable for treatment because their predicted response may be high. The patients on the waiting list who are ideal for antiviral treatment are patients who had no previous treatment, patients who previously responded to treatment, and patients who have low Model for End-stage Liver Disease or Child-Turcotte-Pugh scores. Therapy is discontinued in patients who have no virologic response after 12 weeks. Estimated duration of treatment is 6 months for patients who have genotype 2 or 3 or 12 months for patients who have genotype 1. However, the treatment may be difficult and has limitations in patients who have decompensated cirrhosis, because of frequent and severe treatment-related complications. In addition to the limited efficacy, pegylated interferon may have limited safety in patients who have decompensated cirrhosis. Therapy may be discontinued in 43% patients, and complications during therapy may include decompensation in 29% patients and death in 8% patients. 29 Phase 3 trials of triple therapy based on telaprevir and boceprevir have shown higher frequencies of sustained viral response than pegylated interferon and ribavirin therapy in patients who have advanced fibrosis and cirrhosis. However, the frequency of severe adverse events are higher in patients who receive triple therapy. The frequency of sustained viral response in cirrhotic patients was 62% in the ADVANCE trial, 38% in the ILLUMINATE trial, and 42% in the SPRINT-2 trial. Patients who had compassionate use of protease inhibitors in HCV cirrhosis had higher frequency of major adverse events (30% to 51%) and discontinuation (7% to 12%) in cirrhotic nonresponders than patients in the phase 3 trials. 30 Preventive and preemptive treatment after transplant In contrast with hepatitis B, there is no effective immunoglobulin prophylaxis available for HCV. The HCV immunoglobulin or monoclonal antibody may cause only a transient decrease of liver HCV RNA levels in liver transplant recipients. 31,32 Therefore, prophylactic HCV antibody treatment is not
4 Murat Korkmaz /Experimental and Clinical Transplantation (2014) Suppl 1: recommended currently because of the lack of clinical benefit and the potential for adverse events. Antiviral therapy that is preemptive or early after transplant may prevent the rapid development of chronic hepatitis. It usually is started within 1 to 6 months after liver transplant. Antiviral therapy response is less frequent after transplant in recipients who are positive for HCV than immunocompetent subjects because of the high level of immunosuppression. In 4 studies, different regimens (2 each that used interferon or pegylated interferon monotherapy) had poor efficacy (< 20% sustained viral response) and high frequency of treatment discontinuation and graft rejection. 33 When preemptive therapy is feasible, sustained viral response is obtained in 8% to 39% patients (5% to 33% patients who have genotype 1; 14% to 100% patients who have genotype 2 or 3). The PHOENIX trial showed that preemptive pegylated interferon and ribavirin therapy caused sustained viral response in 12 of 54 patients (22%), and recurrence of HCV at 120 weeks was similar in the prophylaxis (62%) and observation groups. 34 In addition, the frequency of patient and graft survival and biopsyproven acute cellular rejection were similar in the 2 study groups. Most patients (70%) required dose reductions and many patients (30%) discontinued treatment because of adverse events such as bacterial infection, hematologic toxicity, and rejection. A meta-analysis of 11 randomized trials (477 patients) of preemptive treatment in liver transplant recipients who were positive for HCV showed no differences in patient survival, graft rejection, revision transplant, or HCV recurrence between patients who received or did not receive antiviral therapy. 35 Most patients were treated within 26 weeks after liver transplant. Therefore, preemptive treatment currently is not recommended. treatment of established reinfection Liver transplant recipients who have reinfection with HCV may be difficult to treat and cure. 36 Viral recurrence after transplant is characterized by high viral load, accelerated fibrosis, concomitant immunosuppressive treatment, and resistance to interferon. The most effective current treatment protocol includes beginning therapy after the presence of infection is proven by biopsy. Antiviral therapy is started before advanced fibrosis develops because tolerance to therapy decreases markedly in patients who have fibrosis stage > 3. Interferon or ribavirin monotherapy has disappointing results and currently is not advised. In a systematic review of data about 689 patients (27 studies), therapy based on interferon or pegylated interferon caused low mean sustained viral response (24% to 27%) and frequent discontinuation (24% to 26%). 37 However, sustained viral response may be better with therapy based on pegylated interferon than interferon. In patients who have recurrent HCV infection after liver transplant, sustained viral response after therapy based on pegylated interferon is 20% to 40% in patients who have genotype 1, and 50% to 100% in patients who have genotype 2 or In patients diagnosed with fibrosing cholestatic hepatitis, antiviral therapy must be given as early as possible because of the poor short-term prognosis and rapid progression of fibrosis. However, fibrosing cholestatic hepatitis usually is incurable with interferon treatment and prognosis is poor. 39 In 389 liver transplant patients (11 clinical trials) who had HCV recurrence, tolerance to therapy was poor, and there was frequent dose reduction (88%) or discontinuation (43%) because of adverse events or patient preference. 35 There was no difference between treated and control patients in frequency of death, graft rejection, or revision transplant. 35 Patients who were treated with pegylated interferon and ribavirin had higher sustained viral response (48%) than control patients (0%), and improvement in fibrosis was greater in treated patients. The higher sustained viral response may decrease mortality, and this may justify therapy. triple therapy Protease inhibitors for treatment of HCV may provide better results, but experience after liver transplant is limited. Triple therapy based on telaprevir and boceprevir is approved only for infection in patients who have genotype 1; for other patients, recommended treatment includes only pegylated interferon and ribavirin. Telaprevir and boceprevir are potent inhibitors of cytochrome P450, family 3, subfamily A, a key hepatic enzyme that metabolizes many drugs including cyclosporine, sirolimus, and tacrolimus. Therefore, before beginning triple therapy, immunosuppressive doses are decreased and patients are monitored closely for rejection for 4 weeks; after therapy with pegylated interferon and ribavirin for 4 weeks, telaprevir is added for 12 weeks or boceprevir
5 32 Murat Korkmaz /Experimental and Clinical Transplantation (2014) Suppl 1: Exp Clin Transplant is added for 32 weeks. After telaprevir or boceprevir are discontinued, the regular immunosuppressive regimen is resumed. Early reports with few patients have suggested early viral responses, but adverse events are common and potentially life-threatening. In 1 study, early virologic response to triple therapy was 35% with telaprevir (11 patients) and 36% with boceprevir (17 patients), and undetectable HCV RNA levels after 8 weeks were noted in 56% patients who had boceprevir and 70% patients who had telaprevir. 40 The combined results of the ADVANCE and SPRINT- 2 trials suggest that sustained viral response may increase from 30% to 45% with triple therapy. 41 In 37 patients who had HCV recurrence after liver transplant and treated with triple therapy (12 weeks) based on boceprevir (18 patients) or telaprevir (19 patients), some patients had complete viral response (boceprevir, 89%; telaprevir, 58%), end-oftreatment response (boceprevir, 72%; telaprevir, 40%), and sustained viral response (boceprevir, 71%; telaprevir, 20%) (differences not significant). 42 However, treatment failure occurred in 11 patients (30%); 5 patients discontinued therapy because of major adverse events; and 3 patients died. Protease inhibitors are being evaluated in patients who have severe HCV recurrence after liver transplant. 43 At present, triple therapy is used with caution by experienced clinicians at liver transplant centers that may provide very close monitoring for adverse events. revision transplant Liver graft survival is less frequent after revision transplant. Survival is markedly worse for patients who have revision transplant for cirrhosis caused by recurrent HCV infection than other causes. 44 Poor outcomes are associated with high HCV viral load, genotype 1, prior absence of response to treatment, high Model for End-stage Liver Disease score, high serum bilirubin, or high creatinine level. 45 Therefore, revision transplant is not performed in some transplant centers because of organ shortage and probable recurrence in the revised graft. Future Directions Several new drugs currently are being evaluated in clinical trials for treatment of HCV infection, including new types of interferons, second and third generation protease inhibitors, HCV nonstructural 5A protein inhibitors, and polymerase inhibitors. Interferon-free regimens also are being investigated. New drugs under evaluation include the HCV nonstructural 3/4A protease inhibitor simeprevir, HCV nonstructural protein 5B polymerase inhibitor sofosbuvir, and HCV nonstructural 5A protein inhibitor daclatasvir. These drugs may have increased potency and fewer adverse events, and they target unique nonoverlapping components of the HCV replication cycle. The goals of new drug therapy include improved outcomes, decreased adverse events, shortened treatment duration, simplified treatment regimens, and decreased drugdrug interactions. References 1. Kim WR, Terrault NA, Pedersen RA, et al. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology. 2009;137(5): Neumann UP, Berg T, Bahra M, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol. 2004;41(5): Firpi RJ, Clark V, Soldevila-Pico C, et al. The natural history of hepatitis C cirrhosis after liver transplantation. Liver Transpl. 2009;15(9): Taga SA, Washington MK, Terrault N, Wright TL, Somberg KA, Ferrell LD. Cholestatic hepatitis C in liver allografts. Liver Transpl Surg. 1998;4(4): Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002;122(4): Terrault N. Liver transplantation in the setting of chronic HCV. Best Pract Res Clin Gastroenterol. 2012;26(4): Humar A, Kumar D, Raboud J, et al. Interactions between cytomegalovirus, human herpesvirus-6, and the recurrence of hepatitis C after liver transplantation. Am J Transplant. 2002;2(5): Lake JR, Shorr JS, Steffen BJ, Chu AH, Gordon RD, Wiesner RH. Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis. Am J Transplant. 2005;5(3): Ballarin R, Cucchetti A, Spaggiari M, et al. Long-term follow-up and outcome of liver transplantation from anti-hepatitis C virus-positive donors: a European multicentric case-control study. Transplantation. 2011;91(11): Terrault NA, Shiffman ML, Lok AS, et al. Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl. 2007;13(1): Burra P, Loreno M, Russo FP, et al. Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients. Liver Transpl. 2009;15(6): Briceño J, Ciria R, Pleguezuelo M, et al. Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis. Liver Transpl. 2009;15(1): Tambur AR, Ortegel JW, Ben-Ari Z, et al. Role of cytokine gene polymorphism in hepatitis C recurrence and allograft rejection among liver transplant recipients. Transplantation. 2001;71(10):
6 Murat Korkmaz /Experimental and Clinical Transplantation (2014) Suppl 1: Féray C, Caccamo L, Alexander GJ, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology. 1999;117(3): Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology. 1998;28(3): Vargas HE, Laskus T, Wang LF, et al. The influence of hepatitis C virus genotypes on the outcome of liver transplantation. Liver Transpl Surg. 1998;4(1): Zhou S, Terrault NA, Ferrell L, et al. Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia. Hepatology. 1996;24(5): Deshpande V, Burd E, Aardema KL, et al. High levels of hepatitis C virus RNA in native livers correlate with the development of cholestatic hepatitis in liver allografts and a poor outcome. Liver Transpl. 2001;7(2): Shackel NA, Jamias J, Rahman W, et al. Early high peak hepatitis C viral load levels independently predict hepatitis C-related liver failure post-liver transplantation. Liver Transpl. 2009;15(7): Prieto M, Berenguer M, Rayón JM, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology. 1999;29(1): Klintmalm GB, Davis GL, Teperman L, et al. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl. 2011;17(12): Neumann U, Samuel D, Trunečka P, Gugenheim J, Gerunda GE, Friman S. A randomized multicenter study comparing a tacrolimusbased protocol with and without steroids in HCV-positive liver allograft recipients. J Transplant. 2012;2012: doi: /2012/ Berenguer M, Royuela A, Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl. 2007;13(1): Watt KD, Dierkhising R, Heimbach JK, Charlton MR. Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database. Liver Transpl. 2012;18(9): Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl. 2002;8(4): Forns X, García-Retortillo M, Serrano T, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol. 2003;39(3): Everson GT, Trotter J, Forman L, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology. 2005;42(2): Everson GT, Terrault NA, Lok AS, et al. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology. 2013;57(5): Carrión JA, Martínez-Bauer E, Crespo G, et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. J Hepatol. 2009;50(4): Hézode C, Fontaine H, Dorival C, et al. Triple therapy in treatmentexperienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT J Hepatol. 2013;59(3): Davis GL, Nelson DR, Terrault N, et al. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl. 2005;11(8): Schiano TD, Charlton M, Younossi Z, et al. Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study. Liver Transpl. 2006;12(9): Chalasani N, Manzarbeitia C, Ferenci P, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology. 2005;41(2): Bzowej N, Nelson DR, Terrault NA, et al. PHOENIX: a randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl. 2011;17(5): Gurusamy KS, Tsochatzis E, Xirouchakis E, Burroughs AK, Davidson BR. Antiviral therapy for recurrent liver graft infection with hepatitis C virus. Cochrane Database Syst Rev. 2010;1:CD doi: / CD pub Roche B, Sebagh M, Canfora ML, et al. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl. 2008;14(12): Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant. 2006;6(7): Guillouche P, Féray C. Systematic review: anti-viral therapy of recurrent hepatitis C after liver transplantation. Aliment Pharmacol Ther. 2011;33(2): Carrión JA, Navasa M, García-Retortillo M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology. 2007;132(5): Coilly A, Roche B, Botta-Fridlund D, et al. A first multicentric experience of protease inhibitors for severe hepatitis C recurrence after liver transplantation [ILTS abstract O-14]. Liver Transpl. 2012;18(suppl 1):S84-S Burton JR Jr, Everson GT. Management of the transplant recipient with chronic hepatitis C. Clin Liver Dis. 2013;17(1): Coilly A, Roche B, Dumortier J, et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol. 2014;60(1): Epub 2013 Aug 29. doi: /j.jhep Coilly A, Roche B, Samuel D. Current management and perspectives for HCV recurrence after liver transplantation. Liver Int. 2013;33(suppl 1): Roayaie S, Schiano TD, Thung SN, et al. Results of retransplantation for recurrent hepatitis C. Hepatology, 2003;38(6): Neff GW, O Brien CB, Nery J, et al. Factors that identify survival after liver retransplantation for allograft failure caused by recurrent hepatitis C infection. Liver Transpl. 2004;10(12):
Liver Transplantation: The End of the Road in Chronic Hepatitis C Infection
University of Massachusetts Medical School escholarship@umms UMass Center for Clinical and Translational Science Research Retreat 2012 UMass Center for Clinical and Translational Science Research Retreat
More informationLiver transplantation and hepatitis C virus
Liver transplantation and hepatitis C virus Where do we come from? Where are we? Where are we going? François Durand Hépatologie & Réanimation Hépato-Digestive INSERM U1149 Hôpital Beaujon, Clichy HCV:
More informationReview Article Interferon Treatment of Hepatitis C Reinfection after Liver Transplantation: A Meta-Analysis
Gastroenterology Research and Practice Volume 215, Article ID 2632, 8 pages http://dx.doi.org/1.1155/215/2632 Review Article Interferon Treatment of Hepatitis C Reinfection after Liver Transplantation:
More informationImmunosuppressive Strategies in Liver Transplantation for Hepatitis C
Trends in Transplantation Transplant. 2010;4:78-85 Immunosuppressive Strategies in Liver Transplantation for Hepatitis C Timothy M. Clifford 1-3, Michael F. Daily 1,3 and Roberto Gedaly 1,3 1 UK HealthCare,
More informationTREATMENT OF HEPATITIS C IN THE LIVER TRANSPLANT SETTING. Dra. Zoe Mariño Liver Unit. Hospital Clinic Barcelona
TREATMENT OF HEPATITIS C IN THE LIVER TRANSPLANT SETTING Dra. Zoe Mariño Liver Unit. Hospital Clinic Barcelona Hepatitis C after LT Survival (%) HCV negative HCV positive Time from LT (years) HCV treatment
More informationHEPATITIS WEB STUDY. Treatment of Hepatitis C following Liver Transplantation
HEPATITIS WEB STUDY Treatment of Hepatitis C following Liver Transplantation Terry D. Box, MD Associate Professor of Medicine Division of Gastroenterology/Hepatology University of Utah Health Sciences
More informationa series of fact sheets written by experts in the field of liver disease HCV DISEASE PROGRESSION
www.hcvadvocate.org HCSP FACT SHEET Foreword Over years or decades, chronic hepatitis C virus (HCV) infection can progress to severe liver problems including cirrhosis and hepatocellular carcinoma (HCC).
More informationTreatment of Recurrent HCV Infection following Liver Transplantation
Hepatitis C Online PDF created June 27, 2018, 6:09 am Treatment of Recurrent HCV Infection following Liver Transplantation This is a PDF version of the following document: Module 6: Treatment of Special
More informationUnderstanding the Switchbacks: The Impact of Direct Antivirals on the Minimization of Hepatitis C Virus Recurrence After Transplantation
LIVER TRANSPLANTATION 18:S47-S51, 2012 SUPPLEMENT Understanding the Switchbacks: The Impact of Direct Antivirals on the Minimization of Hepatitis C Virus Recurrence After Transplantation David Mutimer
More informationHepatitis C Treatment Before and After Liver Transplant
BJID 2007; 11 Supplement 1 (October) 6 1 Hepatitis C Treatment Before and After Liver Transplant Edson Abdala 1,2, Daniela Rosa Magalhães Gotardo 1, Patrícia Rodrigues Bonazzi 1,2 and Telésforo Bacchella
More informationTreatment of Hepatitis C Recurrence after Liver Transplantation. Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona
Treatment of Hepatitis C Recurrence after Liver Transplantation Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona Agenda 1. Introduction 2. Treatment options for hepatitis C recurrence after transplantation
More informationCase Report of Successful Treatment of Fibrosing Cholestatic Hepatitis C with Sofosbuvir and Ribavirin after Liver Transplantation
108 Diagnostic Problems in Hepatology Case Report of Successful Treatment of Fibrosing Cholestatic Hepatitis C with Sofosbuvir and Ribavirin after Liver Transplantation Brian Kim, MD 1 Anshu Trivedi, MD
More informationEfficacy and safety of protease inhibitors for sever hepatitis C recurrence after liver transplantation: a first multicentric experience
Efficacy and safety of protease inhibitors for sever hepatitis C recurrence after liver transplantation: a first multicentric experience A. Coilly, B. Roche, J. Dumortier, D. Botta-Fridlund, V. Leroy,
More informationDAA-based treatment in cirrhotic and post-transplanted patients. Audrey Coilly, MD Hôpital Paul Brousse, Villejuif, France
DAA-based treatment in cirrhotic and post-transplanted patients Audrey Coilly, MD Hôpital Paul Brousse, Villejuif, France Cirrhosis and transplantation 2 populations with similar issues Hepatic impairment
More informationE nd stage liver disease due to hepatitis C virus infection
248 LIVER DISEASE Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C M Wali, R F Harrison, P J Gow, D Mutimer... Gut 2002;51:248 252 See end of article for
More informationLeading article. Hepatitis C and liver transplantation
Gut 1999;45:159 163 159 Leading article Hepatitis C and liver transplantation Introduction Cirrhosis secondary to hepatitis C virus (HCV) infection, alone or in combination with alcohol, is the principal
More informationAccepted Manuscript. Letter to the Editor. Reply to: From the CUPIC study: Great times are not coming (?)
Accepted Manuscript Letter to the Editor Reply to: From the CUPIC study: Great times are not coming (?) Christophe Hezode, Helene Fontaine, Yoann Barthe, Fabrice Carrat, Jean-Pierre Bronowicki PII: S0-()00-
More informationTransplantation. Professor Didier. Centre Hépatobiliaire, Hépatobiliaire, C.H.B.
Treatment Treatment of of Hepatitis Hepatitis C C in in Liver Liver Transplantation Transplantation Professor Professor Didier Didier Samuel Samuel Centre Centre Hépatobiliaire, Hépatobiliaire, Inserm
More informationOral combination therapy: future hepatitis C virus treatment? "Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside
Author manuscript, published in "Journal of Hepatology 2011;55(4):933-5" DOI : 10.1016/j.jhep.2011.04.018 Oral combination therapy: future hepatitis C virus treatment? Commentary article on the following
More informationChronic hepatitis C virus (HCV) infection is the most common
Treatment of Hepatitis C Virus Infection in Liver Transplant Recipients Duminda Suraweera, MD, Vinay Sundaram, MD, MSc, and Sammy Saab, MD, MPH Dr Suraweera is a resident in the Department of Medicine
More informationAntiviral agents in HCV
Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million
More informationDirect-acting antiviral treatment for hepatitis C in liver transplant candidates and recipients
Editorial Direct-acting antiviral treatment for hepatitis C in liver transplant candidates and recipients Nobuhisa Akamatsu, Junichi Togashi, Kiyoshi Hasegawa, Norihiro Kokudo Artificial Organ and Transplantation
More informationEffect of Calcineurin Inhibitors on Survival and Histologic Disease Severity in HCV-Infected Liver Transplant Recipients
LIVER TRANSPLANTATION 12:762-767, 2006 ORIGINAL ARTICLE Effect of Calcineurin Inhibitors on Survival and Histologic Disease Severity in HCV-Infected Liver Transplant Recipients Marina Berenguer, 1 Victoria
More informationExperience with pre-transplant antiviral treatment: PEG/RBV and DAA. Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona
Experience with pre-transplant antiviral treatment: PEG/RBV and DAA Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona Interferon-free regimens G1b nulls Asunaprevir (PI) + Daclatasvir
More informationSofosbuvir and Simeprevir for Treatment of Recurrent Hepatitis C Infection After Liver Transplant
ARTIcle Sofosbuvir and Simeprevir for Treatment of Recurrent Hepatitis C Infection After Liver Transplant Satheesh Nair, Sanjaya K. Satapathy, Humberto C. Gonzalez Abstract Objectives: Recurrent hepatitis
More informationCurrently, the leading indication for liver transplantation
ORIGINAL ARTICLES Severe Recurrent Hepatitis C After Liver Retransplantation for Hepatitis C Virus Related Graft Cirrhosis Marina Berenguer, * Martín Prieto, * Antonio Palau, * José M. Rayón, Domingo Carrasco,
More informationIL TRAPIANTO DI FEGATO: QUALE FUTURO CON LE NUOVE TERAPIE PER LE MALATTIE EPATICHE?
IL TRAPIANTO DI FEGATO: QUALE FUTURO CON LE NUOVE TERAPIE PER LE MALATTIE EPATICHE? Francesco Paolo Russo Department of Surgery, Oncology and Gastroenterology Multivisceral/ Gastroenterology Section University
More informationTelaprevir-Based Triple Therapy in Liver Transplant Patients With Hepatitis C Virus: A 12-Week Pilot Study Providing Safety and Efficacy Data
LIVER TRANSPLANTATION 18:1464-1470, 2012 ORIGINAL ARTICLE Telaprevir-Based Triple Therapy in Liver Transplant Patients With Hepatitis C Virus: A 12-Week Pilot Study Providing Safety and Efficacy Data Christoph
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE Worldwide Causes of HCC 60% 50% 40% 54% 30% 20% 10% 31% 15% 0% Hepatitis B Hepatitis
More informationHepatitis C: New Antivirals in the Liver Transplant Setting. Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona
Hepatitis C: New Antivirals in the Liver Transplant Setting Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona Patient survival Hepatitis C and Liver Transplantation Years after transplantation
More informationSVR Updates from the 2013 EASL
Updates from the 2013 EASL By Tracy Swan, Treatment Action Group Streamlining HCV Treatment Treatment for hepatitis C virus (HCV) is becoming simpler, shorter, and more effective. All-oral combinations
More informationViral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg
Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic
More informationEvaluating HIV Patient for Liver Transplantation. Marion G. Peters, MD Professor of Medicine University of California San Francisco USA
Evaluating HIV Patient for Liver Transplantation Marion G. Peters, MD Professor of Medicine University of California San Francisco USA Slide 2 ESLD and HIV Liver disease has become a major cause of death
More informationManagement of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy?
Management of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy? Prof. Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of
More informationHepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany
Hepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany PHC 2018 - www.aphc.info Disclosures Advisory boards:
More informationTreatment of HCV Recurrence: Do the Pretransplantation Rules Apply?
LIVER TRANSPLANTATION 12:1044-1048, 2006 EDITORIAL Treatment of HCV Recurrence: Do the Pretransplantation Rules Apply? James R. Burton, Jr., and Hugo R. Rosen Department of Medicine, Division of Gastroenterology
More informationAntiviral treatment in HCV cirrhotic patients on waiting list
Antiviral treatment in HCV cirrhotic patients on waiting list Krzysztof Tomasiewicz Department of Hepatology and Infectious Diseases Medical University of Lublin, Poland Disclosures Consultancy/Advisory
More informationDirectly Acting Antivirals (DAAs) for the Treatment of Chronic Hepatitis C Virus Infection in Liver Transplant Patients: A Flood of Opportunity
American Journal of Transplantation 2014; 14: 994 1002 Wiley Periodicals Inc. Minireview C Copyright 2014 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/ajt.12714
More informationAbstract. Background. Conclusions. Aim. Patients and Methods. Acknowledgments. References. Results. Poster #905
Poster #95 Baseline, Donor, and On-treatment Predictors of Sustained Virologic Response in Treated for Recurrent Hepatitis C Following Orthotopic Liver Transplant: Subanalysis of the PROTECT Study F. D.
More informationIntroduction. The ELECTRON Trial
63rd AASLD November 9-13, 12 Boston, Massachusetts Faculty Douglas T. Dieterich, MD Professor of Medicine and Director of CME Department of Medicine Director of Outpatient Hepatology Division of Liver
More informationSOLAR-1 (Cohorts A and B)
Phase 2 Treatment Naïve and Treatment Experienced Ledipasvir-Sofosbuvir + RBV in HCV GT 1,4 and Advanced Liver Disease SOLAR-1 (Cohorts A and B) Charlton M, al. Gastroenterology. 2015; [Epub ahead of print]
More informationThe role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients
The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients David R. Nelson Clinical and Translational Science Institute, University of Florida, FL, USA Liver International
More informationK For patients who have never been tested for HCV, it is. K It is suggested that HCV-infected patients not previously
http://www.kidney-international.org & 2008 DIGO Guideline 4: Management of HCV-infected patients before and after kidney transplantation idney International (2008) 73 (Suppl 109), S53 S68; doi:10.1038/ki.2008.87
More informationCurrent Status of HBV and Liver Transplant
Current Status of HBV and Liver HBV as Indication for Liver ation in U.S. Significant decrease in rate of wait listing for decompensated cirrhosis since 2003 (since s) No change in rate of wait listing
More informationManagement of Chronic Hepatitis C in Cirrhosis and Liver Transplant Population
46 Jan 2014 Vol 7 No.1 North American Journal of Medicine and Science Review Management of Chronic Hepatitis C in Cirrhosis and Liver Transplant Population Shahid Habib, MD; 1 Obaid Shakil Shaikh, MD 2
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC Mark W. Russo, MD, MPH, FACG Carolinas HealthCare System Charlotte Worldwide Causes of HCC 60% 50% 40% 30% 20% 10% 0% 54% 31% 15% Hepatitis B Hepatitis C
More informationOlysio (simeprivir) Policy Number: Last Review: 09/2017 Origination: 09/2013 Next Review: 09/2018
Olysio (simeprivir) Policy Number: 5.01.604 Last Review: 09/2017 Origination: 09/2013 Next Review: 09/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Olysio (simeprivir)
More informationHepatitis C and liver transplantation
HIPPOKRATIA 2009, 13, 4: 211-215 HIPPOKRATIA PASCHOS 2009, KA 13, 4 211 REVIEW ARTICLE Hepatitis C and liver transplantation Tsoulfas G 1, Goulis I 2, Giakoustidis D 1, Akriviadis E 2, Agorastou P 2, Imvrios
More informationAntiviral therapy guidelines for the general population
Discussion 10 Chapter 10 Hepatitis C a worldwide problem More than 170 million people worldwide suffer from chronic hepatitis C. Its prevalence is 2% in industrialized countries. 1 Approximately 20% of
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationPAPER. Liver Transplant for Hepatitis C Virus. Effect of Using Older Donor Grafts on Short- and Medium-Term Survival
PAPER Liver Transplant for Hepatitis C Virus Effect of Using Older Donor Grafts on Short- and Medium-Term Survival M. B. Majella Doyle, MD; Christopher D. Anderson, MD; Neeta Vachharajani, MD; Jeffrey
More informationTreatment of Hepatitis C in HIV-Coinfected Patients. Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain
Treatment of Hepatitis C in HIV-Coinfected Patients Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain Estimated no. of persons infected with HIV and hepatitis viruses
More informationSOLAR-1 (Cohorts A and B)
Phase 2 Treatment Naïve and Treatment Experienced Ledipasvir-Sofosbuvir + RBV in HCV GT 1,4 and Advanced Liver Disease SOLAR-1 (Cohorts A and B) Charlton M, al. Gastroenterology. 2015; 149:649-59. Ledipasvir-Sofosbuvir
More informationPegylated Interferon Agents for Hepatitis C
Applicable X X X X X X X Pegylated Interferon Agents for Hepatitis C Override(s) Prior Authorization Quantity Limit Initial for Monotherapy or Combination with Ribavirin based on Genotype, Status, or Co-Infection
More informationTreatment of genotype 4 patient. with cirrhosis. Vincent LEROY Clinique Universitaire d Hépato-Gastroentérologie INSERM U823 CHU de Grenoble
Treatment of genotype 4 patient with cirrhosis Vincent LEROY Clinique Universitaire d Hépato-Gastroentérologie INSERM U823 CHU de Grenoble Clinical case 52 year-old patient Intra-venous drug user 1987-1989
More informationImmunosuppression status of liver transplant recipients with hepatitis C affects biopsy-proven acute rejection
pissn 2287-2728 eissn 2287-285X Original Article Clinical and Molecular Hepatology 2016;22:366-371 Immunosuppression status of liver transplant recipients with hepatitis C affects biopsy-proven acute rejection
More informationTreating HCV After Liver Transplantation: What are the Treatment Options?
4 th OPTIMIZE WORKSHOP USING DAAs IN PATIENTS WITH CIRRHOSIS AND LIVER RECIPIENTS Treating HCV After Liver Transplantation: What are the Treatment Options? Maria Carlota Londoño, MD Liver Unit, Hospital
More informationHepatitis C viral (HCV) infection is the leading
Multicenter Experience Using Simeprevir and Sofosbuvir With or Without Ribavirin to Treat Hepatitis C Genotype 1 After Liver Transplant Surakit Pungpapong, 1,2 Bashar Aqel, 3 Michael Leise, 4 K. Tuesday
More informationHarvoni (sofosbuvir/ledipasvir
Market DC Override(s) Prior Authorization Quantity Limit (sofosbuvir/ledipasvir) Approval Duration Based on Genotype, Treatment status, Baseline HCV RNA status, Cirrhosis status, Transplant status, or
More informationViral Hepatitis And Liver Transplantation
Viral Hepatitis And Liver Transplantation Dr.Zeki KARASU Ege University Medical School Dep. Gastroenterology Hepatitis B 3-7 10 % HBV infection in liver transplant recipients, in western countries. 120
More informationMavyret (glecaprevir/pibrentasvir)
(glecaprevir/pibrentasvir) Override(s) Prior Authorization Quantity Limit Medication (glecaprevir/pibrentasvir) Approval Duration Based on Genotype, Treatment Status, or Cirrhosis Status. Quantity Limit
More informationExpress Scripts, Inc. monograph dated 5/25/2011; selected revision 6/1/2011
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Coverage Criteria: Approval Period: Victrelis (boceprevir capsules)
More informationIntron A Hepatitis B. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.01 Subject: Intron A Hepatitis B Page: 1 of 7 Last Review Date: November 30, 2018 Intron A Hepatitis
More informationRECURRENT HEPATITIS C CIRRHOSIS AFTER LIVER TRANSPLANTATION: A NATURAL HISTORY STUDY
RECURRENT HEPATITIS C CIRRHOSIS AFTER LIVER TRANSPLANTATION: A NATURAL HISTORY STUDY By VIRGINIA C. CLARK A THESIS PRESENTED TO THE GRADUATE SCHOOL OF THE UNIVERSITY OF FLORIDA IN PARTIAL FULFILLMENT OF
More informationHCV TREATMENT PRE- AND POST TRANSPLANTATION
HCV TREATMENT PRE- AND POST TRANSPLANTATION Mitchell L. Shiffman, MD, FACG Medical Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA, USA IVer Liver Institute
More informationShould Elderly CHC Patients (>70 years old) be Treated?
Should Elderly CHC Patients (>70 years old) be Treated? Deepak Amarapurkar Consultant Gastroenterologist & Hepatologist Bombay Hospital & Medical Research Center, Mumbai & Jagjivanram Western Railway Hospital,
More informationBidirectional Interaction between Cytomegalovirus and Hepatitis C Virus after Liver Transplantation: A Critical Review of the Clinical Evidence
Trends in Transplantation Transplant. 2008;2:148-56 2008;3 Bidirectional Interaction between Cytomegalovirus and Hepatitis C Virus after Liver Transplantation: A Critical Review of the Clinical Evidence
More informationHow to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy
How to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationHepatitis C Management and Treatment
Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause
More informationDr. Siddharth Srivastava
Dr. Siddharth Srivastava MD, DM (Gastroenterology) Associate Professor GIPMER, New Delhi Rashtriya Gaurav Award 2013 for work on hepatitis B and C Set up Liver clinic at GIPMER and in charge EUS laboratory.
More information2017 UnitedHealthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1146-7 Program Prior Authorization/Notification Medication Harvoni (ledipasvir/sofosbuvir) P&T Approval Date 10/2014, 2/2015,
More informationSafety and Efficacy of Simeprevir Plus Sofosbuvir With or Without Ribavirin in Patients With Decompensated Genotype 1 Hepatitis C Cirrhosis
LIVER TRANSPLANTATION 22:281 286, 2016 ORIGINAL ARTICLE Safety and Efficacy of Simeprevir Plus Sofosbuvir With or Without Ribavirin in Patients With Decompensated Genotype 1 Hepatitis C Cirrhosis Apurva
More informationIncidence and Risk Factors of HCV Recurrence after Living Donor Liver Transplantation
Incidence and Risk Factors of HCV Recurrence after Living Donor Liver Transplantation Mohsen M. Maher 1, Mahmoud S. El-Meteini 2, Mohamed F. Abd Al-Ghaffar 2, Tark M. Yousef, Maha M. Hussein 1, Ahmed I.
More informationMavyret (glecaprevir/pibrentasvir)
Mavyret (glecaprevir/pibrentasvir) Override(s) Approval Duration Prior Authorization Based on Genotype, Treatment Status, or Quantity Limit Cirrhosis Status. **South Carolina, Indiana and Washington Medicaid
More informationTreatment of recurent hepatitis infection after liver transplantation
Paris PHC, 11 janvier 2016 Treatment of recurent hepatitis infection after liver transplantation Georges-Philippe Pageaux CHU Saint Eloi, Digestive department gp-pageaux@chu-montpellier.fr Disclosures
More informationProtease inhibitor based triple therapy in treatment experienced patients
Protease inhibitor based triple therapy in treatment experienced patients Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline Name Olysio (simeprevir) Formulary UnitedHealthcare Community & State Formulary Note Approval Date 2/19/2014 Revision Date 7/9/2014 1. Indications Drug Name: Olysio
More informationIs Treatment cost effective HCV and Organ Transplantation
Is Treatment cost effective HCV and Organ Transplantation Dr Kosh Agarwal Institute of Liver Studies King s College Hospital Barcelona 2016 Disclosures: BoJo Pharma support: AbbVie/Achillion/ Astellas/
More informationInfergen Monotherapy. Infergen (interferon alfacon-1) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.03 Subject: Infergen Monotherapy Page: 1 of 7 Last Review Date: March 13, 2014 Infergen Monotherapy
More informationTopic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015
Medication Policy Manual Policy No: dru332 Topic: Sovaldi, sofosbuvir Date of Origin: March 14, 2014 Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Effective Date: October 1, 2014
More informationSovaldi (sofosbuvir)
Market DC Sovaldi (sofosbuvir) Override(s) Prior Authorization Quantity Limit Approval Duration Based on Genotype, Treatment status, Cirrhosis status, or Ribavirin Eligibility status **IN, SC, WA Medicaid
More informationPharmacological management of viruses in obese patients
Cubist Pharmaceuticals The Shape of Cures to Come Pharmacological management of viruses in obese patients Dr. Dimitar Tonev, Medical Director UKINORD 1 Disclosures } The author is a pharmaceutical physician
More information47 th Annual Meeting AISF
47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,
More informationHepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors
Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center
More informationSAVINO BRUNO, MD Director Internal Medicine and Hepatology Unit AO Fatebenefratelli e Oftalmico, Milano
SAVINO BRUNO, MD Director Internal Medicine and Hepatology Unit AO Fatebenefratelli e Oftalmico, Milano Market wheretelaprevir has not yet launched Victrelis is still launching January 29 th 214 Developed
More informationASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT
ASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT Mitchell L Shiffman, MD Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA Liver Institute of Virginia Education, Research
More informationAn Interferon-free Antiviral Regimen for HCV after Liver Transplantation
The new england journal of medicine original article An Interferon-free Antiviral Regimen for HCV after Liver Transplantation Paul Y. Kwo, M.D., Parvez S. Mantry, M.D., Eoin Coakley, M.D., Helen S. Te,
More informationInfergen (interferon alfacon-1) with Ribavirin (Copegus, Rebetol, RibaPak, Ribasphere, RibaTab, ribavirin tablets/capsules - all strengths)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.04 Subject: Infergen with Ribavirin Page: 1 of 8 Last Review Date: March 13, 2014 Infergen with Ribavirin
More informationNatural History of Clinically Compensated Hepatitis C Virus Related Graft Cirrhosis After Liver Transplantation
Natural History of Clinically Compensated Hepatitis C Virus Related Graft Cirrhosis After Liver Transplantation MARINA BERENGUER, 1 MARTÍN PRIETO, 1 JOSÉ M. RAYÓN, 2 JULIO MORA, 1 MIGUEL PASTOR, 1 VICENTE
More informationGuideline 2: Treatment of HCV infection in patients with CKD Kidney International (2008) 73 (Suppl 109), S20 S45; doi: /ki.2008.
http://www.kidney-international.org & 2008 DIGO Guideline 2: Treatment of HCV infection in patients with CD idney International (2008) 73 (Suppl 109), S20 S45; doi:10.1038/ki.2008.85 Guideline 2.1: Evaluation
More informationHepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More informationBK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy
BK virus infection in renal transplant recipients: single centre experience Dr Wong Lok Yan Ivy Background BK virus nephropathy (BKVN) has emerged as an important cause of renal graft dysfunction in recent
More informationPEARL-I. Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4. Treatment Naïve and Treatment Experienced
Phase 2b Treatment Naïve and Treatment Experienced Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I Hézode C, et al. Lancet. 2015 March 30. [Epub ahead of print] PEARL-I: Study Design
More informationThey are a cure, yes. The good news is that a lot of what I was going to talk about has been covered very nicely this morning. So, I think what I am
They are a cure, yes. The good news is that a lot of what I was going to talk about has been covered very nicely this morning. So, I think what I am going to try to do is give you some examples of some
More informationHepatitis C Update: What s New in 2017
Hepatitis C Update: What s New in 2017 Cody A. Chastain, MD Assistant Professor of Medicine Viral Hepatitis Program Division of Infectious Diseases Vanderbilt University Medical Center Cody.a.Chastain@Vanderbilt.edu
More informationSafety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus
Safety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus JEFFREY NADELSON MD, ALAN EPSTEIN MD, THOMAS SEPE MD BOSTON UNIVERSITY SCHOOL OF MEDICINE ROGER WILLIAMS MEDICAL
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS MAY 217 This information is intended for payers only. The HCV-TARGET study was supported by Gilead Sciences, Inc. Real-world experience data were
More informationSovaldi (sofosbuvir) GA Medicaid
Sovaldi (sofosbuvir) GA Medicaid Override(s) Prior Authorization Quantity Limit Medication Sovaldi (sofosbuvir) Approval Duration Based on Genotype, Treatment status, Cirrhosis status, Hepatocellular Carcinoma
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir ) Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir)
More informationNational Clinical Guidelines for the treatment of HCV in adults. Version 3
National Clinical Guidelines for the treatment of HCV in adults Version 3 January 2017 Sponsors and Authorship The guidelines have been authored on behalf of the viral hepatitis clinical leads and MCN
More information